Skip to main content
Full access
Letter to the Editor
Published Online: 1 December 2004

Mirtazapine and Breast-Feeding

To the Editor: Postpartum depression occurs in approximately 10% of childbearing women, and for many of them, treatment with an antidepressant may be necessary. The benefit of breast-feeding for the infant and the mother is well established; clinicians are therefore asked to make a careful risk-benefit decision on the use of antidepressants. The literature on antidepressants and breast-feeding consists mainly of case series of selective serotonin reuptake inhibitors and tricyclics, whereas information on newer antidepressants is scarce (1). We describe what we believe to be the first reported data on mirtazapine treatment in a breast-feeding woman.
Ms. A, a 27-year-old woman, was admitted to a psychiatric hospital 3 weeks after delivery of her daughter. She was suffering from a severe depressive episode with suicidal thoughts. Ms. A had a history of a first depressive episode at age 18 that was not treated. At the time of admission to the mother-child unit, Ms. A was breast-feeding her child and had so far not received antidepressive treatment. A routine diagnostic assessment, including a physical examination, laboratory studies, and a cerebral computerized tomography scan were normal. Treatment with sertraline, 150 mg/day for 11 weeks, was not effective. Therefore, Ms. A was switched to mirtazapine, 30 mg/day at 9:00 p.m. She fed her infant six times a day. Concentrations of mirtazapine were determined in breast milk and in the serum of mother and infant by using mass spectrometry after Ms. A provided written informed consent and the study was approved by the local ethics committee for measurement of her and her infant’s serum levels of the drug. Samples were taken after reaching steady state before breast-feeding, the first time at 7:00 p.m. (22 hours postdose) and a second time at 12:00 a.m. (15 hours postdose).
At 7:00 p.m., the maternal plasma level of mirtazapine was 7 ng/ml (therapeutic range=5–100 ng/ml); the same level was found in the foremilk (the early portion), whereas in the hindmilk (the later portion), a concentration of 18 ng/ml was detected. On the next day at 12:00 a.m., the maternal plasma concentration was 25 ng/ml; in the foremilk, a concentration of 28 ng/ml and in the hindmilk, 34 ng/ml were found. The infant’s plasma concentration was 0.2 ng/ml. The body weight of the infant was 6.8 kg at this time.
Ms. A was discharged in remission after 6 weeks of mirtazapine treatment. The psychomotor development of the infant was normal, as rated by an experienced neuropediatrician. No adverse events related to the mother’s mirtazapine intake could be detected; especially, there was no sedation or abnormal weight gain.
The results of this case report demonstrate that mirtazapine is excreted into the milk of a nursing mother. No accumulation of mirtazapine in the milk was found. Measured serum concentration in the infant was below therapeutic concentration. We would like to add this information to still incomplete evidence on the safety of antidepressants and breast-feeding.

Reference

1.
Burt VK, Suri R, Altshuler L, Stowe Z, Hendrick VC, Muntean E: The use of psychotropic medications during breast-feeding. Am J Psychiatry 2001; 158:1001–1009

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 2325
PubMed: 15569912

History

Published online: 1 December 2004
Published in print: December 2004

Authors

Affiliations

WOLFGANG AICHHORN, M.D.
ALEXANDRA B. WHITWORTH, M.D.
CHRISTOPH STUPPAECK, M.D.
Innsbruck and Salzburg, Austria

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

There are no citations for this item

View Options

View options

PDF/ePub

View PDF/ePub

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share